Skip to main content
. 2023 Oct 16;18:326. doi: 10.1186/s13023-023-02925-w

Fig. 9.

Fig. 9

The cost-effectiveness acceptability curves of patients with epithelioid histology. CE Cost-effectiveness, E Patients with epithelioid histology, NI Nivolumab plus ipilimumab, C Pemetrexed plus cisplatin/carboplatin